Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease
Konstantinos A. Oikonomou MD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorCorresponding Author
Andreas N. Kapsoritakis MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
M. Alexandrou 66, Terpsithea Larissa, 41500, Larissa, GreeceSearch for more papers by this authorAnastasia I. Kapsoritaki MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorAnastassios C. Manolakis MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorElisavet K. Tiaka MD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorFotios D. Tsiopoulos MD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorIlias A. Tsiompanidis MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorSpiros P. Potamianos MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorKonstantinos A. Oikonomou MD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorCorresponding Author
Andreas N. Kapsoritakis MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
M. Alexandrou 66, Terpsithea Larissa, 41500, Larissa, GreeceSearch for more papers by this authorAnastasia I. Kapsoritaki MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorAnastassios C. Manolakis MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorElisavet K. Tiaka MD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorFotios D. Tsiopoulos MD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorIlias A. Tsiompanidis MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorSpiros P. Potamianos MD, PhD
Department of Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorAbstract
Background:
Angiogenesis is a complex process, involving a great number of mediators. It is implicated in the pathogenesis of numerous diseases, holding a critical role in inflammatory bowel disease (IBD). The objective of this study was to assess serum levels of angiogenin, angiopoietin-1, angiopoietin-2, and endostatin in IBD patients.
Methods:
Measurement of all angiogenesis mediators was performed with a commercially available enzyme-linked immunosorbent assay. Fifty-two patients with ulcerative colitis (UC), 59 with Crohn's disease (CD), and 55 healthy controls (HC) were included in the study. The values were analyzed with regard to disease and patients characteristics.
Results:
Angiogenin levels were significantly higher in IBD patients compared to HC (P < 0.001) and in UC and CD smoker patients compared to nonsmokers (P = 0.0121 and P = 0.005, respectively). Angiogenin levels were lower in UC patients receiving 5-aminosalicylate (5-ASA) alone, compared to those receiving combined therapy (P = 0.0478). Angiopoietin-1 levels were significantly lower in IBD patients compared to HC (P < 0.0001) and increased in smokers compared to nonsmoker UC patients (P = 0.0085). IBD patients demonstrated increased angiopoietin-2 levels compared to HC (P = 0.0131), while CD patients with disease restricted to the colon had significantly lower levels compared to other disease locations (P < 0.0001). Higher endostatin levels were recorded in UC patients with extensive colitis.
Conclusions:
Elevated serum angiogenin and angiopoietin-2 levels and lower serum angiopoietin-1 levels were shown in IBD patients, as well as a different pattern of angiogenic factor alterations related to location, treatment, smoking habits and gender. Inflamm Bowel Dis 2011
REFERENCES
- 1 Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000; 52: 237–268.
- 2 Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001; 61: 253–270.
- 3 Koutroubakis IE, Tsiolakidou G, Karmiris K, et al. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12: 515–523.
- 4 Deban L, Correale C, Vetrano S, et al. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol. 2008; 172: 1457–1466.
- 5 Griga T, Tromm A, Spranger J, et al. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol. 1998; 33: 504–508.
- 6 Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001; 96: 822–828.
- 7 Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis. 2004; 10: 573–577.
- 8 Ferrante M, Pierik M, Henckaerts L, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12: 870–878.
- 9 Sandor Z, Deng XM, Khomenko T, et al. Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun. 2006; 350: 147–150.
- 10 Pousa ID, Maté J, Salcedo-Mora X, et al. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis. 2008; 14: 61–67.
- 11 Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003; 18: 418–422.
- 12 Magro F, Araujo F, Pereira P, et al. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004; 49: 1265–1274.
- 13 Strydom DJ. The angiogenins. Cell Mol Life Sci. 1998; 54: 811–824.
- 14 Badet J. Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties. Pathol Biol (Paris). 1999; 47: 345–351.
- 15 Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry. 1986; 25: 3527–3532 [Erratum 1986; 25: 6730].
- 16 King TV, Vallee BL. Neovascularisation of the meniscus with angiogenin. An experimental study in rabbits. J Bone Joint Surg Br. 1991; 73: 587–590.
- 17 Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277: 55–60.
- 18 Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol. 2001; 20: 319–325.
- 19 Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA. 2002; 99: 8219–8224.
- 20 Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998; 83: 233–240.
- 21 Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell. 2000; 102: 199–209.
- 22 Dallabrida SM, Ismail N, Oberle JR, et al. Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res. 2005; 96: e8–24.
- 23 Li JJ, Huang YQ, Basch R, et al. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost. 2001; 85: 204–206.
- 24 Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell. 2002; 3: 411–423.
- 25 Kim I, Kim JH, Moon SO et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene. 2000; 19: 4549–4552.
- 26 Fiedler U, Krissl T, Koidl S, et al. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem. 2003; 278: 1721–1727.
- 27 Folkman J. Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res. 2006; 312: 594–607.
- 28 Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res. 2001; 7: 3366–3374.
- 29 Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001; 61: 7669–7674.
- 30 Ren B, Höti N, Rabasseda X, et al. The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol. 2003; 25: 215–224.
- 31 Schuch G, Heymach JV, Nomi M, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 2003; 63: 8345–8350.
- 32 O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88: 277–285.
- 33 Hajitou A, Grignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002; 16: 1802–1804.
- 34 Berger AC, Feldman AL, Gnant MF, et al. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res. 2000; 91: 26–31.
- 35 Li Q, Olsen BR. Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice. Am J Pathol. 2004; 165: 415–424.
- 36 van Hensbergen Y, Broxterman HJ, Hanemaaijer R, et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res. 2002; 8: 3747–3754.
- 37 Hebbar M, Peyrat JP, Hornez L, et al. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000; 43: 889–893.
- 38 Koutroubakis IE, Xidakis C, Karmiris K, et al. Serum angiogenin in inflammatory bowel disease. Dig Dis Sci. 2004; 49: 1758–1762.
- 39 Koutroubakis IE, Xidakis C, Karmiris K, et al. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Invest. 2006; 36: 127–132.
- 40 Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998; 43: 29–32.
- 41 Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170: 2–6; discussion 16–19.
- 42 Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439–444.
- 43 Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298: 82–86.
- 44 Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006; 130: 2060–2073.
- 45 Distler JH, Hirth A, Kurowska-Stolarska M, et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003; 47: 149–161.
- 46 Lioté F, Champy R, Moenner M, et al. Elevated angiogenin levels in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblasts. Clin Exp Immunol. 2003; 132: 163–168.
- 47 Martin JW, Mousa SS, Shaker O, et al. The multiple faces of nicotine and its implications in tissue and wound repair. Exp Dermatol. 2009; 18: 497–505.
- 48 Wu WK, Cho CH. The pharmacological actions of nicotine on the gastrointestinal tract. J Pharmacol Sci. 2004; 94: 348–358.
- 49 Kishimoto K, Liu S, Tsuji T, et al. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene. 2005; 24: 445–456.
- 50 Tschesche H, Kopp C, Hörl WH, et al. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem. 1994; 269: 30274–30280.
- 51 Matousek J, Soucek J, Ríha J, et al. Immunosuppressive activity of angiogenin in comparison with bovine seminal ribonuclease and pancreatic ribonuclease. Comp Biochem Physiol B Biochem Mol Biol. 1995; 112: 235–241.
- 52 Roviezzo F, Tsigkos S, Kotanidou A, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther. 2005; 314: 738–744.
- 53 Sturn DH, Feistritzer C, Mosheimer BA, et al. Angiopoietin affects neutrophil migration. Microcirculation. 2005; 12: 393–403.
- 54 Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res. 2009; 335: 205–222.
- 55 Abdollahi A, Hlatky L, Huber PE. Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat. 2005; 8: 59–74.
- 56 Benezra R, Rafii S. Endostatin's endpoints—deciphering the endostatin antiangiogenic pathway. Cancer Cell. 2004; 5: 205–206.
- 57 Wickström SA, Alitalo K, Keski-Oja J. Endostatin signaling and regulation of endothelial cell-matrix interactions. Adv Cancer Res. 2005; 94: 197–229.
- 58 Funatsu H, Yamashita H, Noma H, et al. Stimulation and inhibition of angiogenesis in diabetic retinopathy. Jpn J Ophthalmol. 2001; 45: 577–584.
- 59 Nardo LG. Vascular endothelial growth factor expression in the endometrium during the menstrual cycle, implantation window and early pregnancy. Curr Opin Obstet Gynecol. 2005; 17: 419–423.
